How innovative financing expands access to healthcare in emerging markets

In markets marked by currency volatility, limited access to long term credit, and elevated payment risk, hospitals still need to invest. Clinical demand does not disappear when economic conditions deteriorate, but financing options often do.

By combining Philips technology, Philips Capital’s structured vendor financing, and export credit insurance from Atradius Dutch State Business (Atradius DSB), essential healthcare projects can continue responsibly, even in complex operating environments. The result is tangible impact for hospitals and patients in markets often considered too challenging to support.

In stable economies, financing medical equipment is relatively straightforward. In fragile and volatile markets, however, the challenge is different: weakened credit profiles, sharp currency fluctuations, unpredictable payment channels, and limited availability of long repayment tenors.

Philips Capital structures repayment solutions that align with hospitals’ operational realities, while Atradius DSB provides insurance that mitigates political and commercial payment risks. Together, and supported by experienced local partners, this model enables responsible trade and sustained healthcare investment where it is most challenging and most needed.

Venezuela illustrates this challenge with particular clarity. Years of economic contraction, currency instability, and financial system constraints have made cross border trade and long term financing increasingly difficult. Yet hospitals must continue investing to maintain essential diagnostic and treatment capacity. In 2025, Atradius DSB provided export credit insurance for healthcare projects in Venezuela, enabling Philips Capital to structure financing in a highly uncertain environment. With additional backing from an external guarantor and execution by Philips’ long standing local partner Meditron, hospitals were able to proceed with critical investments rather than defer them¹.

One such transaction supported the first installation in Venezuela of a Philips MR 5300 BlueSeal system at Sagrada Familia in Caracas, completed in the first quarter of 2026. Magnetic Resonance (MR) technology is at the heart of precision diagnostics, supporting the detection, diagnosis, and monitoring of complex conditions. Powered by BlueSeal innovation, the system enables helium-free operations with high-quality imaging, helping clinicians deliver faster, more confident diagnoses while expanding access to advanced imaging services.

In a market where postponement is often the default, this project demonstrates how the right financial structure can sustain access to advanced care and keep critical pathways open.

Argentina’s long standing economic volatility has repeatedly constrained access to long term credit, delaying hospital modernization even when clinical need is clear. At the end of 2024, Atradius DSB reopened export credit insurance coverage for Argentina, creating renewed scope for structured healthcare financing. This decision enabled Philips Capital to support hospitals with financing solutions that met both customer cash flow needs and risk requirements.

For healthcare providers, this translated into a single, integrated proposition: Philips medical technology, vendor supported financing, and export credit insurance in one structure. Projects that had been postponed were able to move forward, unlocking operational efficiencies and improving clinical outcomes through earlier and more accurate diagnosis and treatment.

For credit and risk professionals, the message is clear: sustainable healthcare trade in volatile markets requires more than a willing buyer and a strong product. It requires financial structures that allocate risk transparently, credibly, and responsibly. By pairing Philips Capital’s financing expertise with Atradius DSB’s export credit insurance, and leveraging trusted local execution partners, Philips is enabling hospitals to make essential long term investments even in environments often deemed too risky.

In Venezuela and Argentina, that impact is simple but profound: critical medical equipment delivered, financed under workable terms, and used to improve patient care where it is needed most.